President Donald Trump has announced a new initiative aimed at dramatically reducing the cost of GLP-1 medications for Americans struggling with diabetes and obesity.
On Thursday, Nov. 6, the Trump administration revealed a deal reached with pharmaceutical companies Eli Lilly and Novo Nordisk. Under the agreement, the companies will offer GLP-1 injections for $350 per month to individuals purchasing directly from the manufacturers through the TrumpRx program.
Trump also confirmed that beginning in mid-2026, Medicare and Medicaid recipients will be eligible to pay a reduced monthly price of $245. For those who prefer oral versions of the medication — which are not yet available — the price will be even lower at $149 per month.
Currently, GLP-1 medications cost between $1,000 and $1,350 depending on insurance coverage. Consumers paying out of pocket can already buy directly from manufacturers: Novo Nordisk currently charges $499 per month for all Wegovy doses, while Eli Lilly prices its lowest dose at $349 and higher ones at $499.
:max_bytes(150000):strip_icc():focal(730x395:732x397):format(webp)/Ozempic-costco-040324-1-39bd3838862342a6a82214ff4eb93cc1.jpg)
GLP-1, short for glucagon-like peptide-1, is a hormone used to manage type 2 diabetes and obesity. Semaglutide (marketed as Ozempic and Wegovy) influences the brain’s satiety response, while tirzepatide (sold as Mounjaro and Zepbound) helps suppress appetite and improves the body’s metabolism of sugar and fat. These medications are typically self-injected into the thigh or stomach.
“For years, politicians have talked about making healthcare affordable,” Trump said during an Oval Office press conference. “But my administration is actually doing it.”
He added, “It’s a triumph for American patients that will save lives and improve the health of millions and millions of Americans. Did I do a good job?”
Prior to the announcement, press secretary Karoline Leavitt stated that lowering the cost of obesity drugs had been “a focus the administration has been actively pursuing.” The effort is part of the broader “Make America Healthy Again” initiative designed to combat chronic diseases nationwide.
Trump had previously mentioned his intention to tackle GLP-1 costs back in February, telling Fox News, “The so-called fat drug or fat shot — Ozempic or Mounjaro — costs $88 in London and $1,200 in New York. You can’t even buy it. It’s very unfair … I’m going to solve it one way or the other.”
More recently, Dr. Mehmet Oz, head of the Centers for Medicare and Medicaid Services, confirmed that the administration is “in the middle of a lot of action” negotiating directly with weight-loss drug manufacturers.
